SG10202004094VA - Multivalent fv antibodies - Google Patents

Multivalent fv antibodies

Info

Publication number
SG10202004094VA
SG10202004094VA SG10202004094VA SG10202004094VA SG10202004094VA SG 10202004094V A SG10202004094V A SG 10202004094VA SG 10202004094V A SG10202004094V A SG 10202004094VA SG 10202004094V A SG10202004094V A SG 10202004094VA SG 10202004094V A SG10202004094V A SG 10202004094VA
Authority
SG
Singapore
Prior art keywords
multivalent
antibodies
Prior art date
Application number
SG10202004094VA
Inventor
Kristina Ellwanger
Ivica Fucek
Thorsten Ross
Thomas Mueller
Erich Rajkovic
Uwe Reusch
Martin Treder
Michael Weichel
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of SG10202004094VA publication Critical patent/SG10202004094VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10202004094VA 2015-10-13 2016-10-13 Multivalent fv antibodies SG10202004094VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies

Publications (1)

Publication Number Publication Date
SG10202004094VA true SG10202004094VA (en) 2020-05-28

Family

ID=54325413

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201803083XA SG11201803083XA (en) 2015-10-13 2016-10-13 Multivalent fv antibodies
SG10202004094VA SG10202004094VA (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201803083XA SG11201803083XA (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Country Status (13)

Country Link
US (1) US11572415B2 (en)
EP (2) EP3156417A1 (en)
JP (1) JP6936497B2 (en)
KR (1) KR20180057720A (en)
CN (1) CN108473577A (en)
AU (1) AU2016336866B2 (en)
BR (1) BR112018007445A2 (en)
CA (1) CA3001765A1 (en)
IL (1) IL258638B2 (en)
MX (1) MX2018004547A (en)
SG (2) SG11201803083XA (en)
WO (1) WO2017064221A1 (en)
ZA (1) ZA201802543B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202457A1 (en) 2015-06-15 2016-12-22 Numab Ag Hetero-dimeric multi-specific antibody format
CN117946278A (en) * 2017-06-25 2024-04-30 西雅图免疫公司 Multispecific antibodies and methods of making and using the same
CN111971090B (en) 2018-03-14 2024-02-23 阿菲姆德股份有限公司 Bispecific EGFR/CD16 antigen binding proteins
KR20200139130A (en) * 2018-03-27 2020-12-11 시스트이뮨, 인코포레이티드 Preparation and use of induction and navigation control proteins
WO2019199916A1 (en) * 2018-04-13 2019-10-17 Eli Lilly And Company Fab-based trispecific antibodies
KR20200143436A (en) 2018-04-13 2020-12-23 아피메트 게엠베하 NK cell binding antibody fusion construct
KR20200143730A (en) * 2018-04-17 2020-12-24 인벤라 인코포레이티드 Trivalent trispecific antibody construct
WO2020043670A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
EP4034245A1 (en) * 2019-09-25 2022-08-03 Universität Stuttgart Trivalent binding molecules
US20230002488A1 (en) * 2019-11-06 2023-01-05 Systimmune, Inc. Guidance and navigation control proteins and method of making and using thereof
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
MX2023006573A (en) * 2020-12-03 2023-06-19 Amgen Inc Immunoglobuline constructs with multiple binding domains.
AU2022223152A1 (en) * 2021-02-19 2023-08-31 Innovent Biologics (Suzhou) Co., Ltd. Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CA3232364A1 (en) * 2021-09-29 2023-04-06 Ronnie Rong Wei Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
CN114316060B (en) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 Bispecific antibody against human CD19 and CD206, and preparation method and application thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DE69535719T2 (en) * 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. FAS-ANTIGEN-BINDING LIGAND
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
CA2410551A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
ES2276735T3 (en) 2001-09-14 2007-07-01 Affimed Therapeutics Ag SINGLE CHAIN MULTIMERIC FV ANTIBODIES IN TANDEM.
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CA2657385A1 (en) * 2006-07-13 2008-01-17 Naoki Kimura Cell death inducer
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (en) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma USE OF ANTI-CD71 ANTIBODIES FOR THE PREPARATION OF A MEDICINAL PRODUCT
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
TWI622597B (en) * 2011-03-28 2018-05-01 賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
EP2925782B1 (en) * 2012-12-03 2020-01-22 NovImmune SA Anti-cd47 antibodies and methods of use thereof
US9915665B2 (en) 2012-12-28 2018-03-13 Abbvie Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
WO2016202457A1 (en) * 2015-06-15 2016-12-22 Numab Ag Hetero-dimeric multi-specific antibody format

Also Published As

Publication number Publication date
BR112018007445A2 (en) 2019-12-10
KR20180057720A (en) 2018-05-30
JP6936497B2 (en) 2021-09-15
RU2018126966A (en) 2020-02-10
EP3156417A1 (en) 2017-04-19
CA3001765A1 (en) 2017-04-20
ZA201802543B (en) 2020-01-29
IL258638B (en) 2022-12-01
WO2017064221A1 (en) 2017-04-20
AU2016336866B2 (en) 2023-05-25
AU2016336866A1 (en) 2018-05-10
CN108473577A (en) 2018-08-31
RU2018126966A3 (en) 2020-04-20
JP2018537415A (en) 2018-12-20
MX2018004547A (en) 2018-11-09
US11572415B2 (en) 2023-02-07
SG11201803083XA (en) 2018-05-30
IL258638A (en) 2018-06-28
IL258638B2 (en) 2023-04-01
EP3362478A1 (en) 2018-08-22
US20190040155A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
ZA201802543B (en) Multivalent fv antibodies
HK1253507A1 (en) Anti-ror1 antibodies
HK1254836A1 (en) Anti-ror1 antibodies
HK1254310A1 (en) Anti-garp antibody
GB201521391D0 (en) Antibodies
GB201521393D0 (en) Antibodies
HK1246804A1 (en) Tau-binding antibodies
GB201521382D0 (en) Antibodies
IL256099A (en) Antibody
IL268889A (en) Anti-epha4 antibody
GB201508180D0 (en) Antibodies
GB201515351D0 (en) Antibody
HK1249549A1 (en) Antibody
HUE057499T2 (en) Antibody
GB201600871D0 (en) Antibody
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201513447D0 (en) Antibody
GB201514425D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201508437D0 (en) Antibodies